Ching-yi Chang

Dr. Ching-yi Chang is solving complex problems in the field of pharmacology and cancer biology as an Associate Research Professor at Duke University School of Medicine. Her pioneering research is centered on understanding the intricate roles of nuclear hormone receptors in the development and progression of hormone-related cancers, with a particular emphasis on breast and prostate cancers. Dr. Chang has made significant strides in elucidating the signaling pathways associated with the orphan nuclear receptor estrogen-related receptor alpha (ERRα) in breast cancer. Her work has highlighted ERRα's potential as a promising therapeutic target, offering new avenues for treatment strategies in combating this prevalent disease. Currently, Dr. Chang's research is expanding to explore the effects of modulating ERRα activity within immune cells, such as T cells and macrophages, and their subsequent impact on tumor biology. This innovative approach aims to uncover novel insights into the tumor microenvironment and its interactions with the immune system, potentially leading to groundbreaking advancements in cancer therapy. Through her dedication and expertise, Dr. Chang continues to contribute to the scientific community's understanding of hormone-related cancers, striving to improve patient outcomes and advance the field of cancer biology. Her work not only enhances the knowledge of cancer mechanisms but also paves the way for the development of more effective and targeted therapeutic interventions.